SCHEMBL21991771

SCHEMBL21991771

CCOC(=O)Oc1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP14 P50281 1/20 0.53
ABCB11 O95342 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
HTR2A P28223 1/20 0.51
PMP22 Q01453 1/20 0.51
PPARA Q07869 1/20 0.51
KMT2A Q03164 2/20 0.47
ABCC1 P33527 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
OPRK1 P41145 1/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1808069 0.95 ABCB11 (0.56) MMP2MMP9MMP8MMP14ABCB11
SCHEMBL21991772 0.87 ELANE (0.58) ABCB11CYP1A2CYP3A4TSHRHTR2A
Urethane SCHEMBL21771921 0.87 CYP1A2 (0.49) MMP2MMP9MMP8MMP14ABCB11
SCHEMBL6451238 0.85 ALDH1A1 (0.55) MMP2MMP9MMP8MMP14TSHR
SCHEMBL21991753 0.83 MAOB (0.60) ALDH1A1L3MBTL1MAPTNPC1RAB9A
SCHEMBL21771892 0.81 ABCB11 (0.43) MMP2MMP9MMP8MMP14ABCB11
SCHEMBL21991472 0.81 NPC1 (0.61) ABCB11CYP1A2CYP3A4TSHRHTR2A
SCHEMBL21991485 0.80 MMP2 (0.49) MMP2MMP9MMP8MMP14KMT2A
SCHEMBL1598705 0.80 LMNA (0.57) MMP2MMP9MMP8MMP14KMT2A
SCHEMBL23605660 0.79 FFAR1 (0.45) ABCB11CYP1A2CYP3A4TSHRHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MMP2 885/4885MMP9 416/4885MMP8 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.